Cenegenics Chief Financial Officer Earns MIT’s Executive MBA Degree
Las Vegas, NV (PRWEB) July 17, 2013 -- Rosalind J. Sullivan, Cenegenics’ Chief Financial Officer, graduated from the highly ranked Massachusetts Institute of Technology (MIT), Sloan School of Management, earning an Executive MBA after completing the university’s rigorous 20-month, executive-schedule program, announced Cenegenics, the global leader in age management and recognized leading authority in the field. Sullivan is a CPA and also holds a Master of Science in Finance from Indiana University.
MIT’s challenging executive program focuses on transforming talented leaders into extraordinary executives. Sullivan definitely fits the bill. Over her 13-year tenure, she remained one of the four top executives shouldering the significant responsibilities expected of a large, dynamic organization—one that grew from having a single medical center to 22 centers, 55 full-time/125 part-time physicians, 175 full-time/475 part-time Cenegenics associates and over 20,000 patients worldwide.
"I chose MIT’s Executive MBA program for its emphasis on action learning, merging the theoretical and the practical. Equally important, MIT’s mission statement directly aligns with Cenegenics’ goal. We are a global leader in preventive age management medicine, creating a paradigm shift in medicine away from a disease-centered approach to a proactive one—which ties into MIT’s mission to create innovative leaders who improve the world," Sullivan said.
Per Sullivan, her cohort group at MIT was one of the best parts of the executive program, allowing her to collaborate with a diverse group of students from different industries, business functions and perspectives.
"Working with such a strong team dynamic provided a valuable learning experience that I am taking back to my role as CFO, including an enhanced capacity to explore new strategies and opportunities with my fellow Cenegenics executive team members as we move forward to take our company to even greater heights," Sullivan said.
Completing MIT’s executive program while holding a key position at such a noted company as Cenegenics takes support on all fronts. Sullivan says she is thankful for everyone at Cenegenics as well as her family and parents for their encouragement over the last two years as she worked toward this important milestone in her professional career.
"Cenegenics is extremely proud of Ms. Sullivan’s achievement at MIT. Her ongoing success—professionally, academically and personally—is a testament to her tenacity and commitment for excellence. With good reason, she has earned the utmost respect from all Cenegenics executives and team members. We couldn’t be happier for her," John E. Adams said. Adams is Cenegenics’ cofounder and CEO.
Physicians can discover the rewarding benefits of practicing age management medicine by contacting Cenegenics Director of Physician Recruitment James Powell at 702.321.9716.
Follow Cenegenics on Facebook, Twitter and get health tips, patient celebrity blogs and health news on their portal site, CenegenicsPost.
To schedule an interview with Cenegenics, please contact Ann Castro, Cenegenics Director of Media Relations: 702.953.1588.
About Cenegenics
Cenegenics® has forged a paradigm shift in medicine with its Elite Health Program, developing a proactive medical approach for maximized health, vitality and wellness, hailed as "next generation medicine" and garnering worldwide media attention. Cenegenics has 22 centers with others opening in the near future: Las Vegas, Nevada (headquarters/2 centers); Charleston, SC; Boca Raton, FL; Dallas, TX; Arlington, TX; Atlanta, GA; Chicago, IL; Beverly Hills, CA; Philadelphia, PA; Washington, DC; New York City, NY; Tulsa, OK; Jacksonville, FL; Atlantic City, NJ; Houston, TX; Denver, CO; Scottsdale, AZ; Boston, MA; Miami,FL; Charlotte, NC; San Juan, Puerto Rico; San Francisco, CA. Cenegenics serves over 20,000 patients globally—2,000 are physicians and their families.
Ann Castro, Director of Public Relations, Cenegenics, http://www.cenegenics.com, 702.953.1588, [email protected]
Share this article